Status and phase
Conditions
Treatments
About
To evaluate the safety and tolerability of ART-123 in patients with metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy and bevacizumab
Full description
To compare the safety and tolerability of ART-123 to placebo in patients with metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy and bevacizumab
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
77 participants in 6 patient groups, including a placebo group
Loading...
Central trial contact
Pamela Allton
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal